Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Correlations between Exo-PD-L1, soluble PD-L1 and clinicopathological features

From: Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Characteristics N EXO-PD-L1 N Soluble PD-L1
Low N (%) High N (%) p-value Low N (%) High N (%) p-value
Age (years)     0.528     0.083
 ≤ 60 38 20 (23.53) 18 (21.18)   24 15 (31.25) 9 (18.75)  
 > 60 47 22 (25.88) 25 (29.41)   24 9 (18.75) 15 (31.25)  
Gender     0.063     0.233
 Male 46 27 (32.94) 19 (21.18)   30 17 (35.42) 13 (27.08)  
 Female 39 15 (16.47) 24 (9.41)   18 7 (14.58) 11 (22.92)  
Smoking status     0.138     0.143
 Smoker 26 16 (18.82) 10 (11.77)   14 8 (16.67) 6 (12.50)  
 Non-smoker 59 26 (30.59) 33 (38.82)   34 16 (33.33) 18 (37.50)  
Histology     0.505     0.348
 Squamous carcinoma 12 7 (8.24) 5 (5.88)   5 1 (2.08) 4 (8.33)  
 Adenocarcinoma 73 35 (41.18) 38 (44.70)   43 23 (47.92) 20 (41.67)  
TNM stage     0.012*     0.140
 I 47 29 (34.12) 18 (21.18)   29 17(37.50) 12 (22.92)  
 II/III/IV 38 13 (15.29) 25 (29.41)   19 7 (12.50) 12 (27.08)  
Tumor size (cm)     0.003**     0.004**
 ≤ 2.5 43 28 (32.94) 15 (17.65)   26 18 (37.50) 8 (16.67)  
 > 2.5 42 14 (16.47) 28 (32.94)   22 6 (12.50) 16 (33.33)  
Lymph node status     0.031*     0.131
 N0 53 31 (36.47) 22 (25.88)   31 18 (37.50) 13 (27.08)  
 N1–3 32 11 (12.94) 21 (24.71)   17 6 (12.50) 11 (22.92)  
Distant metastasis     0.026*     0.220
 M0 73 40 (47.06) 33 (38.82)   41 22 (45.83) 19 (39.58)  
 M1 12 2 (2.35) 10 (11.77)   7 2 (4.17) 5 (10.42)  
  1. * p < 0.05, ** p < 0.01